This evening in Kan11 news: Our new COVID-19 preprint - The 4th dose of the BNT162b2 vaccine provides at least 73% protection against SARS-CoV-2 severe illness relative to three doses, during the 9 week outcome period.
Kan11 (in Hebrew)
Mar 26, 2022
Today on N12:
Our new research published today in Annals of Internal Medicine exploring hybrid immunity demonstrated a 82% decreased risk of reinfection among persons who were previously infected and then vaccinated compared to those who were previously infected but remained unvaccinated.
N12 (in Hebrew)
Feb 15, 2022
Today in Annals of Internal Medicine: exploring hybrid immunity demonstrated a 82% decreased risk of reinfection among persons who were previously infected and then vaccinated compared to those who were previously infected but remained unvaccinated.
Annals of Internal Medicine
Feb 15, 2022
We are excited to share that Galit Perez, head of our clinical trials department, was chosen by Globes magazine to the annual list of 40 under 40 most promosing leaders Copy
Globes (In Hebrew)
January 31, 2022
Last call for submissions to our 2022 grant program!
Proposals accepted by the committee will be granted awards up to 400.000 NIS.
For more details, please find the submission form below.
Dec 9, 2021
Nature Medicine magazine published today our joint study with Technion institute: "Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2".
Nov 2, 2021
Published today on Haaretz newspaper: Our joint preprint with Technion institute: "Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine"
Haaretz (In Hebrew)
Sep 19, 2021
Published on Ynet- Our preprint “Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine”
ynet (In Hebrew)
Sep 3, 2021
Published today on Doctorsonly.
Our preprint: "Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections"
Doctorsonly (in Hebrew)
Sep 2, 2021
Published today in Science magazine: our preprint "Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine"
September 1, 2021
Nature News new story - our study assessing the correlation between time-from-vaccine and incidence of breakthrough infection in Nature News. We found that Individuals who were vaccinated in January 2021 had a 2.26-fold increased risk for breakthrough infection compared to individuals who were vaccinated in April 2021
Aug 5, 2021
Our joint research with Tel Aviv University published in JAMA closed an important knowledge gap on the safety and effectiveness of the COVID-19 vaccine, by examining the pregnant population which was excluded from the clinical trials.
July 25, 2021
Our study on COVID-19 vaccine effectiveness in patients with Inflammatory Bowel Disease (IBD), published July 2, 2021 in Gastroenterology—the flagship journal of the American Gastroenterology Association.
July 2, 2021
KSM study in the New York Times!
Our academia-healthcare collaboration with Technion Institute of Technology appearing in the New York Times.
The study "Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals" just published.
New York Times
June 11, 2021
Our joint research with Prof. Roy Kishony and his team from Technion Institute "Community-level evidence for Coronavirus vaccine protection of unvaccinated individuals" published today on Nature Medicine Magazine.
Nature Medicine Magazine
June 10, 2021
A new research by KSM shows most respondents are in favor of vaccinating 12-16 year olds— men more in favor than women. Furthermore, new insights on additional vaccine doses, mask usage stats and more are described.
Doctors Only ( In Hebrew).
June 6, 2021